Our results show that almost half (47%) of the mutations in the PRKAA2 gene that have been reported in cases of human skin cancer and melanoma cause partial or total loss-of-function, reinforcing the hypothesis that such mutations are being selected for in these cancer types. The gene discussed is PRKAA2; the disease is cancer.